Sandoz licenses three Henlius biosimilars for global commercialization
Sandoz has struck a collaboration with Shanghai Henlius to secure commercialization rights outside China for three early-stage biosimilars: evolocumab (Repatha), belimumab (Benlysta) and cetuximab (Erbitux). The agreement includes up to $100.5 million up front for initial assets and up to $322 million total with milestones, while Henlius will continue development and manufacture and retain China rights. The deal raises Sandoz's biosimilars pipeline to 39 assets with potential to reach 46, follows a prior Henlius Yervoy deal, and aligns with Sandoz's plan for a standalone biosimilars unit amid looming patent expiries.
Sandoz gains global rights to three Henlius biosimilars.
Context
Many biologic drugs will lose patent protection in coming years. Sandoz and Henlius have…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorRising cross-border biosimilar…Locked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsFirst regulatory submission outside…Locked
- Probability of ChangeLocked
- Debate PointsComplexity of some biologics may limit…Locked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsWill the companies add more assets to…Locked
- Pros & ConsSandoz: can expand its biosimilars…Locked
Free account — 3 full analyses a day, no card.